<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624557</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719A2105</org_study_id>
    <nct_id>NCT02624557</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Multicenter, Parallel Group Study to Assess the Pharmacokinetics and Safety of Alpelisib (BYL719) in Subjects With Hepatic Impairment Compared to Matched Healthy Control Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics and safety of alpelisib in subjects with hepatic
      impairment compared to matched healthy control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2015</start_date>
  <completion_date type="Actual">October 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameter Cmax</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the maximum plasma concentration (PK parameter Cmax). Cmax directly determined from the plasma concentration-time profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter AUClast</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter AUClast (area under the concentration-time curve from time zero to the last measurable concentration sampling time). AUC determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter AUCinf</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter AUCinf (area under the concentration-time curve from time zero to infinity ). AUC determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter AUC0-t</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter AUC0-t (the partial area under the concentration-time curve from time zero to t hours post dose). AUC determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter tmax</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter tmax (time to reach maximum plasma concentration), directly determined from the plasma concentration-time profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Cl/F</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter Cl/F (apparent oral total drug total plasma clearance calculated from steady-state exposure data ). Cl/F determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Vz/F</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter Vz/F (the apparent volume of distribution during terminal phase). Vz/F determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter T1/2</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Measurement of effect of hepatic impairment on PK of alpelisib by assessment of the PK parameter T1/2 (elimination half-life associated with the terminal slope (lambda-z) of a semi logarithmic concentration-time curve). T1/2 determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between PK parameters Cmax, AUClast, AUCinf and hepatic function parameters</measure>
    <time_frame>predose, 30 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
    <description>Determination of the relationship between the primary PK parameters Cmax, AUClast, AUCinf and baseline hepatic function parameters total bilirubin, INR and serum albumin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events severity and frequency</measure>
    <time_frame>Baseline Day 1 to 30 days post-dose</time_frame>
    <description>Assessment of safety and tolerability of a single dose alpelisib in hepatic impaired subjects compared with healthy matching control subjects by assessing the frequency and severity of adverse events based on the CTCAE criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory parameters</measure>
    <time_frame>Baseline Day 1 to 30 days post-dose</time_frame>
    <description>Assessment of safety and tolerability of a single dose alpelisib in hepatic impaired subjects compared with healthy matching control subjects by assessing the change from baseline in hematological and biochemical laboratory parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG parameters</measure>
    <time_frame>Baseline Day 1 to 30 days post-dose</time_frame>
    <description>Assessment of safety and tolerability of a single dose alpelisib in hepatic impaired subjects compared with healthy matching control subjects by assessing the change from baseline in ECG parameters.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe hepatic impairment with Child-Pugh score 10 - 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching healthy control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>Subjects will receive a single dose of 300 mg alpelisib.</description>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_label>Severe hepatic impairment group</arm_group_label>
    <arm_group_label>Matching healthy control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Other then hepatic impairment, subjects should be in good health as determined by past
        medical history, physical examination, vital signs, electrocardiogram (except for
        additional inclusion criteria for hepatic impaired subjects). -Subjects must weigh at least
        50 kg and no more than 120 kg and have a body mass index in the range 18.0-36.0 kg/m2.

        Additional criteria for hepatic impaired subjects: -Subjects must have a score clinically
        determined and calculated as per the Child-Pugh classification and consistent with the
        degree of hepatic impairment in which study is currently enrolling. -Stable Child-Pugh
        status within 28 days prior to dosing.

        Exclusion Criteria: All subjects:

          -  Subject has received a liver transplant at any time in the past and is on
             immunosuppressant therapy.

          -  Smokers not willing to limit the use of tobacco to 10 cigarettes per day. -Surgical or
             medical condition which might significantly alter the absorption, distribution,
             metabolism, or excretion of drugs, or which may jeopardize the subject's safety in
             case of participation in the study. -Use of any herbal medications/supplements.

        History of acute pancreatitis within 1 year of study entry.

        Additional criteria for subjects with normal liver function:

        -Use of any prescription or non-prescription medication. -Positive Hepatitis B surface
        antigen (HBsAg) or Hepatitis C test result.

        Additional criteria for hepatic impaired subjects: -Use of any prescription or
        non-prescription medication, that has the potential to interact with alpelisb. Concomitant
        medications without potential to interact with alpelisib must be stable in dose.
        -Encephalopathy grade 3 or worse. -Total bilirubin &gt; 6 mg/dl. Screening or baseline ECG:
        QTcF&gt;480msec for both genders

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research-Denver</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami / Clinical Research Services, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Clinical pharmacology study</keyword>
  <keyword>BYL719</keyword>
  <keyword>alpelisib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

